Rita Taylor Stewart
Physician Assistant · van Horne, IANPI 1003891086
Payments from drug & device makers
Across 137 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$511
- Amgen$345
- Pfizer$209
- AbbVie$150
- Novo Nordisk$148
- Lilly USA, LLC$135
- plus $648 from 17 others
What the payments were for
- Food & beverage$2,146100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $511 |
| Amgen | 30 | $345 |
| Pfizer | 12 | $209 |
| AbbVie | 9 | $150 |
| Novo Nordisk | 9 | $148 |
| Lilly USA, LLC | 9 | $135 |
| Exact Sciences | 8 | $129 |
| Mylan Specialty L.p. | 7 | $92 |
| Merck | 3 | $50 |
| Boehringer Ingelheim | 3 | $41 |
| Johnson & Johnson | 2 | $39 |
| Bayer | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Genentech USA, Inc. | 2 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$2,146 in reported general payments places this provider in the 85th percentile of 1,140 physician assistant providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $126,762 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $51,045 |
| XareltoRivaroxaban | 36 | $33,211 |
| Nucynta ErTapentadol Hcl | 18 | $30,450 |
| JardianceEmpagliflozin | 13 | $19,968 |
| FarxigaDapagliflozin Propanediol | 21 | $19,598 |
| RybelsusSemaglutide | 13 | $15,375 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $12,444 |
| Levothyroxine Sodium | 287 | $2,740 |
| Omeprazole | 208 | $2,514 |
| Losartan Potassium | 217 | $2,419 |
| Gabapentin | 81 | $2,095 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,072 |
| Potassium Chloride | 78 | $1,881 |
| Atorvastatin Calcium | 214 | $1,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $148 | $142,137134 claims |
| Johnson & JohnsonXarelto | $39 | $33,21136 claims |
| Boehringer IngelheimJardiance | $41 | $19,96813 claims |
| AstraZenecaFarxiga | $511 | $19,59821 claims |
| GSKBreo Ellipta | $12 | $12,44434 claims |
| AbbVieSynthroid | $150 | $59114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in van Horne
- Jayson GesulgaUrbandale$878K
- Laurie ClairJohnston$293K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
- Kelly MerchieDavenport$15K
- Kathleen DuffyClive$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.